Genetically Engineering Cyanobacteria for the Production of Sulfated Polysaccharide

Why It Matters

The technology provides a carbon‑neutral, scalable alternative for producing sulfated polysaccharides, reducing ecological impact and diversifying supply chains for pharma, cosmetics, and material industries.

Key Takeaways

• Gene cluster from Synechocystis transferred to Synechococcus elongatus
• Engineered strain secretes extracellular sulfated polysaccharide synechan
• Production shifts metabolism toward stress response, affecting growth
• Method offers renewable alternative to animal‑derived sulfated polysaccharides
• Platform enables future design of custom biomaterials via photosynthesis

Pulse Analysis

Sulfated polysaccharides (SPS) such as hyaluronic acid and carrageenan underpin a multibillion‑dollar market spanning pharmaceuticals, cosmetics, and functional foods. Traditionally these polymers are harvested from animal tissues or marine algae, a process that strains ecosystems and raises supply‑chain volatility. Researchers have therefore been hunting microbial platforms that can convert CO₂ into high‑value biomolecules using sunlight. The recent work from the Institute of Science Tokyo and Tokyo University of Agriculture demonstrates that cyanobacteria—photosynthetic microbes already employed in biofuel research—can be repurposed as green cell factories for SPS production.

The team identified the complete synechan biosynthetic gene cluster in the model cyanobacterium Synechocystis sp. PCC 6803 and transplanted it into Synechococcus elongatus PCC 7942, a strain prized for its genetic tractability and rapid growth. The engineered cells began secreting extracellular synechan that matched the structure of the native polymer, confirming functional integration of a complex, multi‑gene pathway. Metabolomic profiling revealed a shift toward stress‑response pathways and modest growth attenuation, highlighting the metabolic burden of polysaccharide synthesis but also offering targets for future optimization.

This proof‑of‑concept opens a pathway to replace animal‑derived SPS with a carbon‑neutral, scalable process that leverages sunlight and CO₂. By fine‑tuning promoter strength, pathway balancing, and cultivation conditions, yields could approach industrial relevance, attracting investment from biotech firms seeking sustainable raw materials. Moreover, the modular nature of the gene cluster suggests that custom sulfation patterns and polymer lengths can be engineered, enabling bespoke biomaterials for drug delivery, wound healing, or biodegradable coatings. As regulatory pressure mounts for greener manufacturing, cyanobacterial SPS platforms are poised to become strategic assets in the bio‑economy.